260 related articles for article (PubMed ID: 27058899)
1. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Casadei Gardini A; Marisi G; Faloppi L; Scarpi E; Foschi FG; Iavarone M; Lauletta G; Corbelli J; Valgiusti M; Facchetti F; Della Corte C; Neri LM; Tamberi S; Cascinu S; Scartozzi M; Amadori D; Nanni O; Tenti E; Ulivi P; Frassineti GL
Oncotarget; 2016 May; 7(19):27988-99. PubMed ID: 27058899
[TBL] [Abstract][Full Text] [Related]
2. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
Gardini AC; Faloppi L; Aprile G; Brunetti O; Caparello C; Corbelli J; Chessa L; Bruno D; Ercolani G; Leonetti A; Stefano G; Farella N; Foschi FG; Lanzi A; Dadduzio V; Marisi G; Masi G; Negri FV; Pagan F; Santini D; Scarpi E; Silletta M; Silvestris N; Tamburini E; Tassinari D; Vivaldi C; Gentilucci UV; Zagonel V; Calvetti L; Cascinu S; Frassineti GL; Scartozzi M
Tumori; 2018 Dec; 104(6):476-479. PubMed ID: 29739298
[TBL] [Abstract][Full Text] [Related]
3. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
4. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
5. The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.
Zheng YB; Zhan MX; Zhao W; Liu B; Huang JW; He X; Fu SR; Zhao Y; Li Y; Hu BS; Lu LG
Med Oncol; 2014 Oct; 31(10):209. PubMed ID: 25182707
[TBL] [Abstract][Full Text] [Related]
6. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
[TBL] [Abstract][Full Text] [Related]
7. Association of
Casadei-Gardini A; Marisi G; Dadduzio V; Gramantieri L; Faloppi L; Ulivi P; Foschi FG; Tamburini E; Vivaldi C; Rizzato MD; Ielasi L; Canale M; Conti F; Rudnas B; Fornaro L; Silvestris N; Silletta M; Cardellino GG; Lonardi S; Fornari F; Orsi G; Rovesti G; Zagonel V; Cascinu S; Scartozzi M
Clin Cancer Res; 2020 Sep; 26(17):4485-4493. PubMed ID: 32371540
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
9. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
10. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):733-9. PubMed ID: 25376291
[TBL] [Abstract][Full Text] [Related]
11. The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.
Shao YY; Chang YL; Huang CY; Hsu CH; Cheng AL
Oncology; 2013; 85(5):312-6. PubMed ID: 24217400
[TBL] [Abstract][Full Text] [Related]
12. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
[TBL] [Abstract][Full Text] [Related]
13. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Casadei Gardini A; Scarpi E; Faloppi L; Scartozzi M; Silvestris N; Santini D; de Stefano G; Marisi G; Negri FV; Foschi FG; Valgiusti M; Ercolani G; Frassineti GL
Oncotarget; 2016 Oct; 7(41):67142-67149. PubMed ID: 27613839
[TBL] [Abstract][Full Text] [Related]
14. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Inoue M; Wakamatsu T; Tawada A; Yokosuka O
PLoS One; 2016; 11(8):e0161303. PubMed ID: 27537374
[TBL] [Abstract][Full Text] [Related]
18. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Satani M; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Koga H; Torimura T;
Oncotarget; 2016 Sep; 7(39):64400-64409. PubMed ID: 27462865
[TBL] [Abstract][Full Text] [Related]
19. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Lee YS; Kim BH; Kim BC; Shin A; Kim JS; Hong SH; Hwang JA; Lee JA; Nam S; Lee SH; Bhak J; Park JW
Oncotarget; 2015 Jun; 6(18):16449-60. PubMed ID: 25965825
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
Ziogas DC; Papadatos-Pastos D; Thillai K; Korantzis I; Chowdhury R; Suddle A; O'Grady J; Al-Khadimi G; Allen N; Heaton N; Ross PJ; Sarker D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):48-55. PubMed ID: 27623000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
